UNSPSC 51172013: Febuprol

This classification denotes a cholagogue or choleretic agent with the molecular formula C13H20O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B5RKR9Y63Y, chemically known as 2-propanol, 1-n-butoxy-3-phenoxy- but generally known as febuprol, which bears US NIH Compound Identifier 71119. European Medicines Agency schedules Febuprol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07520MIG.

UNSPSC 51172013 Febuprol is a Commodity code covering pharmaceutical products that state and local governments procure primarily through drug testing programs, pharmacy benefit initiatives, and multistate cooperative purchasing agreements. Recent solicitations show state and local buyers purchasing febuprol—a nonsteroidal anti-inflammatory drug—as part of broader specimen screening and pharmaceutical supply contracts. Issuing bodies span state health and human services commissions, county corrections and community supervision departments, and multistate cooperative purchasing alliances representing participating state and local agencies. The work encompasses laboratory-based drug screening services with pharmaceutical testing components, direct-to-manufacturer pharmacy benefit programs, and generic pharmaceutical supply chains serving government facilities and health plans.

Activity appears concentrated in Texas and the Upper Midwest. The Texas Health and Human Services Commission issued an RFI in April 2026 exploring direct-to-manufacturer prescription programs, and Collin County Community Supervision and Corrections Department issued an RFP in July 2026 for offender specimen collection and drug testing services (RFP 2026-327, due July 23, 2026, estimated value $600,000 over two years with three optional one-year renewals). The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products to serve participating state and local government facilities in Minnesota and Oregon (RFP S1070000015802, proposals due March 26, 2026). The Collin County solicitation requires SAMHSA, Texas DPS, or CAP lab certification and prices on a per-test basis across multiple screening and confirmation service models; MMCAP requires cGMP and Drug Supply Chain Security Act compliance with pricing flexibility through net-price and WAC-minus structures.